81
Participants
Start Date
October 18, 2007
Primary Completion Date
February 22, 2008
Study Completion Date
February 22, 2008
Treatment sequence A
Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fed state
Treatment sequence B
Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fed state
Treatment sequence C
Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fasted state
Treatment sequence D
Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fasted state
GSK Investigational Site, Evansville
GSK Investigational Site, Austin
Lead Sponsor
GlaxoSmithKline
INDUSTRY